Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Jun 23;40(1):294.
doi: 10.1007/s10103-025-04547-z.

Comparative efficacy of 450 nm blue-laser vaporization versus transurethral plasma kinetic enucleation of the prostate (TUPKEP) for benign prostatic hyperplasia in high-risk elderly patients: a focus on safety, efficacy, and sexual function preservation

Song Li  1   2 , Chuang Fu  3 , Xiaoqiang Liu  4 , Junqing Hou  5
Affiliations
Comparative Study

Comparative efficacy of 450 nm blue-laser vaporization versus transurethral plasma kinetic enucleation of the prostate (TUPKEP) for benign prostatic hyperplasia in high-risk elderly patients: a focus on safety, efficacy, and sexual function preservation

Song Li et al. Lasers Med Sci. .

Abstract

Objective: To explore the clinical efficacy, safety, and potential value for preserving sexual function of the 450 nm advanced blue-laser device in the treatment of high - risk and elderly patients with benign prostatic hyperplasia (BPH).

Methods: Analysis was conducted on 161 elderly and high-risk patients with BPH who underwent surgical treatment. They were divided into the blue-lasergroup (77 cases) and the Transurethral Plasma Kinetic Enucleation of the Prostate (TUPKEP) (84 cases). The general data of the patients in both groups were collected, including age, TPSA, prostate volume, and comorbidities. Subsequently, intraoperative and postoperative indicators of the two groups were compared, including Qmax, IPSS, QoL scores before and after treatment, and complications.

Results: The perioperative indicators of the patients in the 450 nm blue-lasergroup, namely the operation time and intraoperative blood loss, were 40.70 ± 15.44 min and 22.74 ± 19.98 ml, respectively, which were significantly lower than those of the TUPKEP group (81.61 ± 33.50 min and 65.45 ± 70.87 ml). The overall incidence of complications in the TUPKEP group was higher than that in the 450 nm blue-laser group, mainly manifested in transient urinary incontinence, sexual function, etc. The IIEF-5 score of the laser group at 3 months after surgery was significantly higher than that of the plasma enucleation group (17.04 ± 2.01). There was no significant difference in the comparison of Qmax, IPSS score, and QoL between the two groups at 3 months after surgery (P > 0.05).

Conclusion: The 450 nm blue-laser vaporization for the treatment of high-risk BPH has advantages such as convenient operation, definite curative effect, and fewer complications.

Keywords: BPH; Blue laser; TUPKEP; TURP.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval: Ethical clearance to conduct this study was obtained from the Institutional Ethics Committee. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Competing interests: The authors declare no competing interests. Conflict of interest: None. Human ethics and consent to participate: Informed written consent was obtained from the patients to allow their participation/use for research purposes. Registry and the Registration No. of the study/trial: None. Animal Studies: None.

References

    1. Kucukdurmaz F, Efe E, elik A et al (2017) Evaluation of serum prolidase activity and oxidative stress markers in men with BPH and prostate cancer BMC. Urol 17(1):116
    1. Nunes RV, Manzano J, Truzzi JC et al (2017) Treatment of benign prostatic hyperplasia. Rev Assoc Med Bras(1992) 63(2):95–99 - DOI - PubMed
    1. Pushkar DY, Bernikov AN, Khodyreva LA et al (2018) Quality of life in patients with lower urinary tract symptoms after TURP for benign prostatic hyperplasia. Urologiia.; (1): 53–61
    1. Amu OC, Affusim EA, Nnadozie UU, Nwachukwu CD (2023) Outcome of transurethral resection of the prostate (TURP) using 5% dextrose water as irrigant. Niger J Clin Pract 26(10):1568–1574 - DOI - PubMed
    1. Xu X, Jiang D, Liu G et al (2022) In vitro evaluation of the safety and efficacy of a high-power 450-nm semiconductor blue-laserin the treatment of benign prostate hyperplasia. Lasers Med Sci 37(1):555–561 - DOI - PubMed

Publication types

LinkOut - more resources